慢性髓性白血病何时考虑同种异体移植

Daniel Egan, Jerald Radich
{"title":"慢性髓性白血病何时考虑同种异体移植","authors":"Daniel Egan,&nbsp;Jerald Radich","doi":"10.1002/acg2.85","DOIUrl":null,"url":null,"abstract":"<p>Allogeneic stem cell transplantation (ASCT) has historically been recognized as the only curative therapy for chronic myeloid leukemia (CML). However, the remarkable success of tyrosine kinase inhibitors (TKIs) which result in excellent long-term disease control in the majority of newly diagnosed CML patients, has forever changed the treatment strategy of CML. However, TKIs fail some patients, due to treatment resistance, relapse, progression, and toxicity, and for these patients ASCT remains a potentially curative option. In this review, we will discuss the indications and outcomes of allogeneic transplant for patients with CML in the modern era.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"3 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.85","citationCount":"1","resultStr":"{\"title\":\"When to consider allogeneic transplant for chronic myeloid leukemia\",\"authors\":\"Daniel Egan,&nbsp;Jerald Radich\",\"doi\":\"10.1002/acg2.85\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Allogeneic stem cell transplantation (ASCT) has historically been recognized as the only curative therapy for chronic myeloid leukemia (CML). However, the remarkable success of tyrosine kinase inhibitors (TKIs) which result in excellent long-term disease control in the majority of newly diagnosed CML patients, has forever changed the treatment strategy of CML. However, TKIs fail some patients, due to treatment resistance, relapse, progression, and toxicity, and for these patients ASCT remains a potentially curative option. In this review, we will discuss the indications and outcomes of allogeneic transplant for patients with CML in the modern era.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"3 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.85\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.85\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.85","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

异基因干细胞移植(ASCT)历来被认为是治疗慢性髓性白血病(CML)的唯一方法。然而,酪氨酸激酶抑制剂(TKIs)在大多数新诊断的CML患者中取得了良好的长期疾病控制的显著成功,永远改变了CML的治疗策略。然而,由于治疗抵抗、复发、进展和毒性,TKIs使一些患者失败,对于这些患者,ASCT仍然是一种潜在的治疗选择。在这篇综述中,我们将讨论现代CML患者异体移植的适应症和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
When to consider allogeneic transplant for chronic myeloid leukemia

Allogeneic stem cell transplantation (ASCT) has historically been recognized as the only curative therapy for chronic myeloid leukemia (CML). However, the remarkable success of tyrosine kinase inhibitors (TKIs) which result in excellent long-term disease control in the majority of newly diagnosed CML patients, has forever changed the treatment strategy of CML. However, TKIs fail some patients, due to treatment resistance, relapse, progression, and toxicity, and for these patients ASCT remains a potentially curative option. In this review, we will discuss the indications and outcomes of allogeneic transplant for patients with CML in the modern era.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信